Skip to content Skip to footer
Subscribe Now
Verastem Oncology New
NEWS

Verastem Oncology Reports First Patient Dosing with VS-7375  in P-I/IIa Study for KRAS G12D Advanced Solid Tumors

Shots: Verastem reported the dosing of the first patient (US) for P-I/IIa study (VS-7375-101) assessing the safety, tolerability, and efficacy of VS-7375 The dose-escalation phase of the study starts at 400mg, based on results from a P-I/II study conducted by GenFleet in China, and presented initial safety and efficacy data at ASCO’25 Upon reaching the…
June 25, 2025

Read more

Astellas & Evopoint Bio
NEWS

Astellas Enters a ~$1.54B Licensing Agreement with Evopoint Biosciences to Develop & Commercialize XNW27011

Shots: Evopoint Biosciences has granted Astellas exclusive license to develop & commercialize XNW27011 globally, excl. Mainland China, Hong Kong, Macao & Taiwan As per the deal, Evopoint will receive $130M upfront as well as ~$70M as near-term payments in addition to ~$1.34B in development, regulatory & commercial milestones, with net sales-based royalties XNW27011, an CLDN18.2-specific…
May 30, 2025

Read more

UTR Therapeutics
NEWS

UTR Therapeutics Seeks the US FDA’s IND Clearance of UTRxM1-18 to Target c-MYC-Driven Cancers

Shots: The US FDA has received the IND application for UTRxM1-18, a novel therapy targeting c-MYC-driven cancers, to initiate P-I trial in 2026 pending approval, focusing on c-MYC driven tumors incl. triple-negative breast, pancreatic, colorectal, & ovarian cancer UTRxM1-18 has demonstrated strong, dose-dependent efficacy against human-derived tumors from multiple cancer subtypes, with no dose-limiting toxicities…
May 9, 2025

Read more

NEWS

Silexion Therapeutics Reports Preclinical Data for SIL-204 in Combination with 1L Chemotherapies for Pancreatic Cancer

Shots: Silexion reported preclinical data of SIL-204 (siRNA agent) + 5-fluorouracil + irinotecan & SIL-204 + gemcitabine combinations in KRAS G12D mutated human pancreatic tumor cell lines The data demonstrated a reduction in cancer cell confluence in contrast to 1L CT agents alone, where SIL-204 + 5-fluorouracil + irinotecan achieved reduction after 3 days…
January 16, 2025

Read more

Innovent
NEWS

Innovent’s IBI343 Secures the NMPA’s Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Shots: The NMPA has granted BTD to IBI343 alone for treating CLDN18.2+ advanced pancreatic ductal adenocarcinoma (PDAC) progressed post 1L of systematic therapy Designation was based on the ongoing P-I trial of IBI343 (6mg/kg, Q3W) in CLDN18.2+ advanced PDAC patients (n=43) treated with at least 1L of therapy (5% received 2L+ of therapy) across…
January 16, 2025

Read more

Disease of the Month - Pancreatic Cancer
INSIGHTS+

Disease of the Month – Pancreatic Cancer

Shots To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the Disease of the Month, PharmaShots brings a condensed report on Pancreatic Cancer  November 16th is observed as World Pancreatic Cancer…
December 18, 2023

Read more

VIEWPOINTS_Moitreyee Chatterjee-Kishore_2023
VIEWPOINTS

Moitreyee Chatterjee-Kishore, in an absorbing conversation with PharmaShots, shares the highlights of the SPOTLIGHT & GLOW study

Shots:   Moitreyee Chatterjee-Kishore, HOD, Immuno-Oncology & Cancer Cell Therapy at Astellas shares insights from the P-III trials (SPOTLIGHT & GLOW)   In SPOTLIGHT and GLOW, zolbetuximab and chemotherapy demonstrated improved PFS and OS vs placebo plus chemotherapy, yielding positive outcomes for patients with advanced gastric or GEJ cancer.   Moitreyee highlights the ongoing clinical trials for the…
November 29, 2023

Read more

Viewpoint_Dr.Jing_Watnick_&_Dr. Lou_Vaickus_2021
VIEWPOINTS

PharmaShots Interview: Vigeo Therapeutics’ Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 2020

In a recent interview with PharmaShots, Dr. Jing Watnick, Co-Founder and Chief Executive Officer, and Dr. Lou Vaickus, Interim Chief Medical Officer at Vigeo shared their views on the data findings presented at the SITC 2020 Annual Meeting that demonstrated VT1021 as a single-agent has a favorable safety profile and shows early signals of clinical activity across a wide variety of…
January 15, 2021

Read more